CN Patent

CN104350049B — 作为激酶抑制剂的取代氨基喹唑啉

Assigned to Suzhou Taolue Biotechnology Co ltd · Expires 2016-07-13 · 10y expired

What this patent protects

本发明公开了一类新型喹唑啉以及其衍生物、药学上可接受的盐、前药和水合物。本发明的这些化合物及及其组合物具有蛋白激酶抑制活性并且将有益于蛋白激酶介导的疾病或者病症的治疗。

USPTO Abstract

本发明公开了一类新型喹唑啉以及其衍生物、药学上可接受的盐、前药和水合物。本发明的这些化合物及及其组合物具有蛋白激酶抑制活性并且将有益于蛋白激酶介导的疾病或者病症的治疗。

Drugs covered by this patent

Patent Metadata

Patent number
CN104350049B
Jurisdiction
CN
Classification
—
Expires
2016-07-13
Drug substance claim
No
Drug product claim
No
Assignee
Suzhou Taolue Biotechnology Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.